GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alpha Teknova Inc (NAS:TKNO) » Definitions » EV-to-EBITDA

Alpha Teknova (Alpha Teknova) EV-to-EBITDA : -3.19 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Teknova EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alpha Teknova's enterprise value is $81.58 Mil. Alpha Teknova's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.54 Mil. Therefore, Alpha Teknova's EV-to-EBITDA for today is -3.19.

The historical rank and industry rank for Alpha Teknova's EV-to-EBITDA or its related term are showing as below:

TKNO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -175.4   Med: -5.4   Max: 128.32
Current: -3.19

During the past 5 years, the highest EV-to-EBITDA of Alpha Teknova was 128.32. The lowest was -175.40. And the median was -5.40.

TKNO's EV-to-EBITDA is ranked worse than
100% of 707 companies
in the Drug Manufacturers industry
Industry Median: 14.72 vs TKNO: -3.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Alpha Teknova's stock price is $1.9537. Alpha Teknova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.160. Therefore, Alpha Teknova's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Alpha Teknova EV-to-EBITDA Historical Data

The historical data trend for Alpha Teknova's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Teknova EV-to-EBITDA Chart

Alpha Teknova Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -54.58 -6.19 -6.04

Alpha Teknova Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.19 -3.31 -3.53 -4.07 -6.04

Competitive Comparison of Alpha Teknova's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alpha Teknova's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alpha Teknova's EV-to-EBITDA falls into.



Alpha Teknova EV-to-EBITDA Calculation

Alpha Teknova's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=81.580/-25.539
=-3.19

Alpha Teknova's current Enterprise Value is $81.58 Mil.
Alpha Teknova's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpha Teknova  (NAS:TKNO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Alpha Teknova's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.9537/-1.160
=At Loss

Alpha Teknova's share price for today is $1.9537.
Alpha Teknova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.160.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Alpha Teknova EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Alpha Teknova's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Teknova (Alpha Teknova) Business Description

Traded in Other Exchanges
N/A
Address
2451 Bert Drive, Hollister, CA, USA, 95023
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification.
Executives
Ken Gelhaus officer: Chief Commercial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Stephen Gunstream director, officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
J Matthew Mackowski director 343 SANSOME ST, SUITE 1215, SANSASAN FRANCISCO CA 94104
Matthew Lowell officer: Chief Financial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Damon Terrill officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
Thp Iv Affiliates Fund, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Lisa Hood officer: Chief People Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Irene Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Ted Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Iv, L.p. 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO MA 94108
Paul David Grossman director 1600 FARADAY AVENUE, CARLSBAD CA 92008
Brett Robertson director C/O INVUITY, INC., 444 DE HARO STREET, SAN FRANCOSCO CA 94107
Alexander C. Herzick director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Management Company, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108